Список литературы

scan of families with prostate cancer identifies multiple regions of interest. Am. J. Hum. Genet., 2000, v. 67, p. 100—109.

Going J.J., Gusterson B.A. Molecular pathology and future developments. Eur. J. Cancer, 1999, v. 35, p. 1895—1904.

Golka K., Prior V., Blaszkewicz M., Bolt H.M. The enhanced bladder cancer susceptibility of NAT2 slow acetylators towards aromatic amines: a review considering ethnic differences. Toxicol. Lett., 2002, v. 128, p. 229-241.

Golub T.R., Slonim D.K., Tamayo P., HuardC., Gaasenbeek M., Mesirov J.P., Collar H., Loh M.L., Downing J.R., Caligiuri M.A., Bloomfield C.D., Lander E.S. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 1999, v. 286, p. 531-537.

Goode E.L., Stanford J.L., Chakrabarti L., Gibbs M., Kolb S., Mclndoe R.A., Buckley V.A., Schuster E.F., NealC.L., MillerE.L., BrandzelS., HoodL., OstranderE.A., Jarvik G.P. Linkage analysis of 150 high-risk prostate cancer families at lq24-25. Genet. Epidemiol., 2000, v. 18, p. 251—275.

Goodman A. Role of routine human papillomavirus subtyping in cervical screening. Curr. Opin. Obstet. Gynecol., 2000, v. 12, p. 11—14.

Gordon M.S. Novel antiangiogenic therapies for renal cell cancer. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6377S-6381S.

Gore R.M., Berlin J. W., Mehta U.K., Newmark G.M., Yaghmai V. GI carcinoid tumours: appearance of the primary and detecting metastases. Best Pract. Res. Clin. Endocrinol. Metab., 2005, v. 19, p. 245-263.

Gori S., Porrozzi S., Roila F., Gatta G., De Giorgi U., Marangolo M. Germ cell tumours of the testis. Crit. Rev. Oncol. Hematol., 2005, v. 53, p. 141—164.

Goss P. Anti-aromatase agents in the treatment and prevention of breast cancer. Cancer Control, 2002, v. 9 (2 Suppl.), p. 2—8.

Grady W. M., Markowitz S. D. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics. Hum. Genet., 2002, v. 3, p. 101—128.

Graziano F., Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ В colorectal cancer patients: how much evidence is enough? Ann. Oncol., 2003, v. 14, p. 1026-1038.

Greene M.H. Genetics of breast cancer. Mayo Clin. Proc., 1997, v. 72, p. 54— 65.

Greenlee R.T., Murray T., Bolden S., Wingo P.A. Cancer statistics, 2000. CA Cancer J. Clin., 2000, v. 50, p. 7—33.

Grundy P, Coppes M. An overview of the clinical and molecular genetics of Wilms’ tumor. Med. Pediatr. Oncol., 1996, v. 27, p. 394—397.

Guilhot F. /ndications for imatinib mesylate therapy and clinical management. Oncologist, 2004, v. 9, p. 271—281.

Habuchi T., LiqingZ., Suzuki T.., Sasaki R., Tsuchiya N., TachikiH., Shimoda N., Satoh S., Sato K., Kakehi Y, Kamoto T., Ogawa O., Kato T. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res., 2000, v. 60, p. 5710—5713.

Haggman M.J., Macoska J.A., Wojno K.J., Oesterling J.E. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J. Urol., 1997, v. 158, p. 12-22.

Hagmar B., Kalantari M., Skyldberg B., Moberger B., Johansson B., Walaas L., Warleby B. Human papillomavirus in cell samples from Stockholm gynecologic health screening. Acta Cytologica, 1995, v. 39, p. 741-745.

HalachmiS., Madeb R., Kravtsov A., MoskovitzB., Halachmi N., NativO. Bladder cancer — genetic overview. Med. Sci. Monit., 2001, v. 7, p. 164-168.

Hall J., Angele S. Radiation, DNA damage and cancer. Mol. Med. Today, 1999, v. 5, p. 157-164.

Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell, 2000, v. 100, p. 57— 70.

Harley С. B., Villeponteau B. Telomeres and telomerase in aging and cancer. Curr. Opin. Genet. Dev., 1995, v. 5, p. 249-255.

Harris N.L., Jajfe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L., DelsolG., De Wolf-PeetersC., Falini B., GatterKC. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994, v. 84, p. 1361-1392.

Harris N.L., Stein H., Coupland S.E., Hummel M., Favera R.D., Pasqualucci L., Chan W.C. New approaches to lymphoma diagnosis. Hematology (Am Soc Hematol Educ. Program), 2001, p. 194-220.

Haydon A.M., Jass J.R. Emerging pathways in colorectal-cancer development. Lancet Oncol., 2002, v. 3, p. 83—88.

Hedenfalkl., Duggan D., Chen Y., RadmacherM., BittnerM., Simon R., MeltzerP., Gusterson B., EstellerM., Kallioniemi O.P., Wilfond B., Borg A., Trent J., Raffeld M., YakhiniZ., Ben-Dor A., Dougherty E., KononenJ., BubendorfL., Fehrle W, PittalugaS., GruvbergerS., Loman N., Johannsson O., Olsson H., SauterG. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med., 2001, v. 344, p. 539—548.

Herrington C.S. Human papillomaviruses and cervical neoplasia. 1. Classification, virology, pathology, and epidemiology. J. Clin. Pathol., 1994, v. 47, p. 1066—1072.

Hesketh R. The oncogene and tumor suppressor gene factsbook. San Diego, Academic Press, 1997.

Hilleman M.R. Overview of vaccinology with special reference to papillomavirus vaccines. J. Clin. Virol., 2000, v. 19, p. 79-90.

Hochhaus A. Minimal residual disease in chronic myeloid leukaemia patients. Best Pract Res. Clin. Haematol., 2002, v. 15, p. 159—178.

Hodi F.S., Dranoff G. Genetically modified tumor cell vaccines. Surg. Oncol. Clin. N. Am., 1998, v. 7, p. 471-485.

Holly E.A. Cervical intraepithelial neoplasia, cervical cancer and HPV. Annu. Rev. Public. Health., 1996, v. 17, p. 69—84.

HoneckerF.,OosterhuisJ.W., MayerF., Hartmann J.T., BokemeyerC., Looijenga L.H. New insights into the pathology and molecular biology of human germ cell tumors. World J. Urol., 2004, v. 22, p. 15-24.

Список литературы

Houlston R.S. What we could do now: molecular pathology of colorectal cancer. Mol Pathol., 2001, v. 54, p. 206—214.

Hsing A.W., Gao Y.T., Wu G., Wang X., Deng J., Chen Y.L., Sesterhenn I.A., Mostofi F.K., BenichouJ., Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res., 2000, v. 60, p. 5111—5116.

HuangS., Afonina I., Miller B.A., Beckmann A. M. Human papillomavirus types 52 and 58 are prevalent in cervical cancers from Chinese women. Int. J. Cancer, 1997, v. 70, p. 408-411.

Hung R.J., Boffetta P., Brockmoller J., Butkiewicz D., Cascorbi I., Clapper M.L., Garte S., Haugen A., Hirvonen A., Anttila S., Kalina /., Le Marchand L., London S.J., RannugA., Romkes M., Salagovic J., Schoket B., Gaspari L., Taioli E. CYP1A1 and GSTM genetic polymorphisms and lung cancer risk in Caucasian nonsmokers: a pooled analysis. Carcinogenesis, 2003, v. 24, p. 875—882.

Iacopetta B. Are there two sides to colorectal cancer? Int J. Cancer, 2002, v. 101, p. 403-408.

Ichihara M., Murakumo Y., Takahashi M. RET and neuroendocrine tumors. Cancer Lett., 2004, v. 204, p. 197—211.

Imyanitov E.N., Suspitsin E.N., Grigoriev M.Yu., Togo A.V., Kuligina E.Sh., Belogubova E.V., Pozharisski K.M., Turkevich E.A., Rodriguez C., Cornelisse C.J., Hanson K.P., TheilletC. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int. J. Cancer, 2002, v. 100, p. 557-564.

Imyanitov E.N., Hanson K.P. Molecular pathogenesis of bilateral breast cancer. Cancer Lett., 2003, v. 191, p. 1—7.

Imyanitov E.N., Togo A.V., Hanson K.P. Searching for cancer-associated gene polymorphisms: promises and obstacles. Cancer Lett., 2004, v. 204, p. 3—14.

Imyanitov E.N., Hanson K.P. Mechanisms of breast cancer. Drug Discov. Today: Dis. Mech., 2004, v. I, p. 235-245.

Imyanitov E.N. Kuligina E.Sh., Belogubova E.V., Togo A.V., Hanson K.P. Mechanisms of lung cancer. Drug Discov. Today: Dis. Mech., 2005, v. 2, p. 213— 223.

Imyanitov E., Hanson K, Zhivotovsky B. Polymorphic variations in apoptotic genes and cancer predisposition. Cell Death Differ., 2005, v. 12, p. 1004—1107.

Ingvarsson S. Molecular genetics of breast cancer progression. Semin. Cancer Biol., 1999, v. 9, p. 277-288.

Infante-Rivard C., LabudaD., Krajinovic M., SinnettD. Risk of childhood leukemia associated with exposure to pesticides and with gene polymorphisms. Epidemiology, 1999, v. 10, p. 481-487.

Innocenti F., Ratain M.J. «Irinogenetics» and UGT1A: from genotypes to haplotypes. Clin. Pharmacol. Then, 2004, v. 75, p. 495—500.

Innocenti F., Yokes E.E., Ratain M.J. Irinogenetics: what is the right star? J. Clin. Oncol., 2006, v. 24, p. 2221-2224.

Jackson A.L., Loeb L.A. The mutation rate and cancer. Genetics, 1998, v. 148, p. 1483-1490.

Jaffe E.S., Harris N.L., Stein H. (eds.). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France, IARC Press, 2001.

Jenkins D. Diagnosing human papillomaviruses: recent advances. Curr. Opin. Infect. Dis., 2001, v. 14, p. 53-62.

Jones R.H., Vasey P.A. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. Eur. J. Cancer, 2003, v. 39, p. 147-156.

Jordan V.C. Is tamoxifen the Rosetta stone for breast cancer? J. Natl. Cancer Inst., 2003, v. 95, p. 338-340.

Jordan V.C. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell, 2004, v. 5, p. 207-213.

Jung /., Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control, 2000, v. 7, p. 325—334.

Junker K., Wiethege T., Muller K.M. Pathology of small-cell lung cancer. J. Cancer Res. Clin. Oncol., 2000, v. 126, p. 361—368.

Iwase H., Greenman J.M., Barnes D.M., Hodgson S., Bobrow L., Mathew C.G. Sequence variants of the estrogen receptor (ER) gene found in breast cancer patients with ER negative and progesterone receptor positive tumors. Cancer Lett., 1996, v. 108, p. 179-184.

Kabalin J.N., McNeal J.E., Price H.M., Freiha P.S., Stamey T.A. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J. Urol., 1989, v. 141, p. 1091-1094.

Kaelin W.G. Jr. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6290S-6295S.

Kohlenberg M.S., Sullivan J.M., WitmerD.D., PetrelliN.J. Molecular prognostics in colorectal cancer. Suig. Oncol., 2003, v. 12, p. 173—186.

Kallioniemi A., Kallioniemi O.P., SudarD., Rutovitz D., GrayJ. W., Waldman F., Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science, 1992, v. 258, p. 818-821.

Kallioniemi O.P. Biochip technologies in cancer research. Ann. Med., 2001, v. 33, p. 142-147.

KaltsasG., RockallA., Papadogias D., ReznekR., Grossman A.B. Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. Eur. J. Endocrinol., 2004, v. 151, p. 15—27.

KaHsson R., Jonsson M., EdlundK., EvanderM., GustavssonA., Boden E., RylanderE., Wadell G. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population-based study. Sex. Transm. Dis., 1995, v. 22, p. 119-127.

Kawakami K, Graziano F, WatanabeG., RuzzpA., SantiniD., Catalano V, BisonniR., Arduini F., Bearzi /., Cascinu S., Muretto P., Perrone G., Rabitti C., Giustini L., Tonini G.,

Список литературы

Pizzagalli F., Magnani M. Prognostic role of thymidylate synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy. Clin. Cancer Res., 2005, v. 11, p. 3778—3783.

Kaye F.J. Molecular biology of lung cancer. Lung Cancer, 2001, v. 34, Suppl. 2, p. S35-S41.

Kaye F.J. A curious link between epidermal growth factor receptor amplification and survival: effect of «allele dilution» on gefitinib sensitivity? J. Natl. Cancer Inst., 2005, v. 97, p. 621-623.

KeladaS.N., KardiaS.L., WalkerA.H., WeinA.J., MalkowiczS.B., Rebbeck T.R. The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking. Cancer Epidemiol Biomarkers Prev., 2000, v. 9, p. 1329—1334.

Kerangueven F, Noguchi T, Coulter F., Allione F, Wargniez V., Simony-Lafontaine J., Longy M., Jacquemier J., Sobol H., Eisinger F., Bimbaum D. Genome-wide search for loss of heterozygosity shows extensive genetic diversity of human breast carcinomas. Cancer Res., 1997, v. 57, p. 5469-5474.

Khan J., Simon R., Bittner M., Chen Y., Leighton S.B., Pohida T., Smith P.D., Jiang Y., Gooden G.C., Trent J.M., MeltzerP.S. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. Cancer Res., 1998, v. 58, p. 5009— 5013.

Khrapko K.R., Lysov Yu.P., KhorlynA.A., Shick V. V, Florentiev V.L., MirzflbekovA.D. An oligonucleotide hybridization approach to DNA sequencing. FEBS Lett., 1989, v. 256, p. 118-122.

Kim H.L., Belldegrun A.S., Figlin R.A. Immune gene therapy for kidney cancer: the search for a magic trigger. Mol Ther., 2003, v. 7, p. 153-154.

Kim S.J., Miyoshi Y, Taguchi T., Tamaki Y., Nakamura H., Yodoi J., Kato K, Noguchi S. High thioredoxin expression is associated with resistance to docetaxel in primary breast cancer. Clin. Cancer Res., 2005, v. 11, p. 8425-8430.

Kim S.K., Ro J.Y., Kemp B.L., Lee J.S., Kwon T.J., Hong W.K., Mao L. Identification of two distinct tumor-suppressor loci on the long arm of chromosome 10 in small cell lung cancer. Oncogene, 1998, v. 17, p. 1749-1753.

KinzlerK. W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell, 1996, v. 87, p. 159-170.

Kishimoto M., Kohno T., Okudela K, OtsukaA., Sasaki H., TanabeC., Sakiyama T., Hirama C., Kitabayashi /., Minna J.D., Takenoshita S., Yokota J. Mutations and deletions of the СВР gene in human lung cancer. Clin. Cancer Res., 2005, v. 11(2 Pt 1), p. 512-519.

KjaerS.K, Jensen O.M. Comparison studies of HPVdetection in areas at different risk for cervical cancer. In: Munoz N., Bosch F.X., Shah K.V., Meheus A. (eds.) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 243-249.

Knowles M.A. What we could do now: molecular pathology of bladder cancer. Mol. Pathol., 2001, v. 54, p. 215-221.

Knudson A.G. Jr. Hereditary cancers disclose a class of cancer genes. Cancer, 1989, v. 63, p. 1888-1891.

Koivisto P, KolmerM., Visakorpi T., Kallioniemi O.P. Androgen receptor gene and hormonal therapy failure of prostate cancer. Am. J. Pathol., 1998, v. 152, p. 1-9.

Kondo Y, Issa J.P. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev., 2004, v. 23, p. 29-39.

KongF.M., AnscherM.S., Washington M.K., Killian J.K., Jirtle R.L.. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene, 2000, v. 19, p. 1572— 1578.

Korfee S., Gauler T., Hepp R., Pottgen C., Eberhardt W. New targeted treatments in lung cancer — overview of clinical trials. Lung Cancer, 2004, v. 45, Suppl. 2, p. S199-S208.

Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Medicine, 1997, v. 102, p. 3—8.

Kristensen V.N., Andersen T.I., Lindblom A., Erikstein B., Magnus P, Borresen-DaleA.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics, 1998, v. 8, p. 43-48.

KuklinA., Shah S., Hoff B., Shams S. Information processing issues and solutions associated with microarray technology. Lab. Robotics Automations, 2000, v. 12, p. 317-327.

Kulke M.H. Neuroendocrine tumours: clinical presentation and management of localized disease. Cancer Treat. Rev., 2003, v. 29, p. 363—370.

Lake D.E., Hudis C. Aromatase inhibitors in breast cancer: an update. Cancer Control, 2002, v. 9, p. 490—498.

Lam J.S., Belldegrun A.S., Figlin R.A. Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6304S-6309S.

Lavigne J.A., Helzlsouer K.J., Huang H. Y., Strickland P T., Bell D.A., Selmin O., Watson M.A., Hoffman S., Comstock G.W., Yager J.D. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res., 1997, v. 57, p. 5493-5497.

Lawes D.A., SenGupta S., Boulos P.B. The clinical importance and prognostic implications of microsatellite instability in sporadic cancer. Eur. J. Surg. Oncol., 2003, v. 29, p. 201-212.

Lawrie L.C., Fothergill J.E., Murray G.I. Spot the differences: proteomics in cancer research. Lancet Oncol., 2001, v. 2, p. 270—277.

LeethanakulC., Patel V., Gillespie J., Pallente M., EnsleyJ.F., Koontongkaew S., Liotta L.A., Emmert-Buck M., Gutkind J.S. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene, 2000, v. 19, p. 3220-3224.

LengauerC., KinzlerK. W., Vogelstein B. Genetic instabilities in human cancers. Nature, 1998, v. 396, p. 643-649.

Список литературы

Leo A., Cardoso F., Durbecq V., Giuliani R., Mono M., Atalay G., Larsimont D., Sotiriou C, Biganzoli L., Piccart M.J. Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002. Int. J. Clin. Oncol.,

2002, v. 7, p. 245-253.

Leotlela P.D., JauchA., Holtgreve-Grez H., ThakkerR. V. Genetics of neuroendocrine and carcinoid tumours. Endocr. Relat. Cancer, 2003, v. 10, p. 437—450.

Lerebours F., Lidereau R. Molecular alterations in sporadic breast cancer. Crit. Rev. Oncol. Hematol., 2002, v. 44, p. 121 — 141.

Lerman C, Berrettini W. Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am. J. Med. Genet. В Neuropsychiatr. Genet.,

2003, v. 118, p. 48-54.

Li C., Larsson C., FutrealA., Lancaster J., Phelan C., Aspenblad U., Sundelin B., Liu Y, Ekman P, AuerG., Bergerheim U.S. Identification of two distinct deleted regions on chromosome 13 in prostate cancer. Oncogene, 1998, v. 16, p. 481—487.

LiF.P., GarberJ.E., FriendS.H., StrongL.C., PatenaudeA.F., JuengstE.T., Reilly P.R., Correa P, Fraumeni J.F. Jr. Recommendations on predictive testing for germ-line p53 mutations among cancer-prone individuals. J. Natl. Cancer Inst., 1992, v. 84, p. 1156-1160.

Lidereau R., EscotC., TheilletC., Champeme M.H., BrunetM., GestJ., Callahan R. High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J. Natl. Cancer Inst., 1986, v. 77, p. 697—701.

Lievre A., Bachet J.B., Le Corre D., Boige V., Landi B., Emile J.F., Cote J.F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res., 2006, v. 66, p. 3992—3995.

LigibelJ.A, Winer E.P. Clinical differences among the aromatase inhibitors. Clin. Cancer Res., 2003, v. 9 (1 Pt 2), p. 473S-479S.

Lindahl T., Nyberg B. Rate of depurination of native deoxyribonucleic acid. Biochemistry, 1972, v. 11, p. 3610-3618.

Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr. Opin. Oncol., 2001, v. 13, p. 63-69.

Linehan W.M., Vasselli J., Srinivasan R., Walther M.M., Merino M., Choyke P., Vocke C., Schmidt L., Isaacs J.S., Glenn G., Toro J., ZbarB., Bottom D., Neckers L. Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6282S-6289S.

Linehan W.M., ZbarB. Focus on kidney cancer. Cancer Cell, 2004, v. 6, p. 223— 228.

Linet M.S., Pottern L.M. Familial aggregation of hematopoietic malignancies and risk of non-Hodgkin’s lymphoma. Cancer Res., 1992, v. 52, p. 5468s—5473s.

Liotta L., Petricoin E. Molecular profiling of human cancer. Nat. Rev. Genet., 2000, v. 1, p. 48-56.

Lipshutz R.J., Fodor S.P., Gingeras T.R., Lockhart D.J. High density synthetic oligonucleotide arrays. Nat. Genet., 1999, v. 21, p. 20—24.

Liu L., Gerson S.L. Targeted modulation of MGMT: clinical implications. Clin. Cancer Res., 2006, v. 12, p. 328—331.

Lo S., Johnston S.R. Novel systemic therapies for breast cancer. Surg. Oncol., 2003, v. 12, p. 277-287.

Lockhart D.J., Winzeler E.A. Genomics, gene expression and DNA arrays. Nature, 2000, v. 405, p. 827-836.

Lorincz A. T. Detection of human papillomavirus DNA without amplification: prospects for clinical utility. In: Munoz N., Bosch F.X., Shah K.V., MeheusA. (eds.) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 135-145.

Lossos I.S., Czerwinski D.K., Alizadeh A.A., WechserM.A., Tibshirani R., Botstein D., Levy R. Prediction of survival in diffuse large-В-cell lymphoma based on the expression of six genes. N. Engl. J. Med., 2004, v. 350, p. 1828—1837.

Lutke Holzik M.F., Rapley E.A., Hoekstra H.J., SleijferD. T., Nolte I.M., Sijmons

R.H. Genetic predisposition to testicular germ-cell tumours. Lancet Oncol., 2004, v. 5, p. 363-371.

Lynch T.J., Bell D. W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B. W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, v. 350, p. 2129-2139.

Ma P.C., Jagadeeswaran R., Jagadeesh S., Tretiakova M.S., Nallasura V., FoxE.A., Hansen M., Schaefer E., Naoki K., Lader A., Richards W., Sugarbaker D., Husain A.N., Christensen J.G., Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res., 2005, v. 65, p. 1479-1488.

MacGrogan G., Rudolph P., Mascarel Id.I., Mauriac L., Durand M., Avril A., Dilhuydy J.M., Robert J., Mathoulin-Pelissier S., Picot V., Floquet A., Sierankowski G., CoindreJ.M. DNAtopoisomerase Ilalpha expression and the response to primary chemotherapy in breast cancer. Br. J. Cancer, 2003, v. 89, p. 666-671.

Mack P.C., Davies A.M., Lara P.N., Gumeriock P.H., Gandara D.R. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer. Lung Cancer, 2003, v. 41, Suppl 1, p. S89-S96.

Macri E., Loda M. Role of p27 in prostate carcinogenesis. Cancer Metastasis Rev., 1998-1999, v. 17, p. 337-344.

Maehama T., Asato T., Kanazawa K. Prevalence of H PV infection in cervical cytology-normal women in Okinawa, Japan, as determined by a polymerase chain reaction. Int. J. Gynaecol. Obstet., 2000, v. 69, p. 175—176.

Maione P., Rossi A., Airoma G., Ferrara C., Castaldo V., Gridelli C. The role of targeted therapy in non-small cell lung cancer. Crit. Rev. Oncol. Hematol., 2004, p. 51, v. 29-44.

Manos M.M., Ting Y., Wright D.K. Use of polymerase chain reaction for detection of genital human papillomavirus. Cancer Cells, 1989, v. 7, p. 209—214.

Список литературы

Mariatos G., Bothos J., Zacharatos P., Summers M.K., Scolnick D.M., Kittos C., Halazonetis T.D., Gorgoulis V.G. Inactivating mutations targeting the chfr mitotic checkpoint gene in human lung cancer. Cancer Res., 2003, v. 63, p. 7185—7189.

Marsh D.J., Mulligan L.M., EngC. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Horm. Res., 1997, v. 47, p. 168-178.

Marsh S., McLeod H.L.. Cancer pharmacogenetics. Br. J. Cancer, 2004, v. 90,

p. 8-11.

Marsh S. Thymidylate synthase pharmacogenetics. Invest. New Drugs, 2005, v. 23, p. 533-537.

MartelC.L., Lara P. N. Renal cell carcinoma: current status and future directions. Crit. Rev. Oncol. Hematol., 2003, v. 45, p. 177-190.

Masramon L., Ribas M., Cifuentes P, Arribas R., Garcia F., Egozcue J., Peinado M.A., Miro R. Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. Cancer Genet. Cytogenet., 2000, v. 121, p. 17-21.

Mass R.D. The HER receptor family: a rich target for therapeutic development. Int. J. Radiat. Oncol. Biol. Phys., 2004, v. 58, p. 932—940.

Masters J.R., Koberle B. Curing metastatic cancer: lessons from testicular germcell tumours. Nat. Rev. Cancer, 2003, v. 3, p. 517-525.

Matsuyama H., Pan Y., Skoog L., Tribukait B., Naito K., Ekman P, Lichter P., Bergerheim U.S. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene, 1994, v. 9, p. 3071—3076.

Mayer F., Honecker F., Looijenga L.H., BokemeyerC. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann. Oncol., 2003, v. 14, p. 825—832.

McCue P.A., Gorstein F. Genetic markers in renal cell carcinomas. Hum. Pathol., 2001, v. 32, p. 1027-1028.

McDonnell T.J., Navone N.M., Troncoso P., Pisters L.L., ContiC., von Eschenbach A.C., Brisbay S., Logothetis C.J. Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer. J. Urol., 1997, v. 157, p. 569-574.

McLaughlin F., Finn P, La Thangue N.B. The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov. Today, 2003, v. 8, p. 793-802.

McMurray H.R., Nguyen D., Westbrook T.F., McAnce D.J. Biology of human papillomaviruses. Int. J. Exp. Pathol., 2001, v. 82, p. 15—33.

MeijerC.J.L.M., van den Brule A.J.C., Shijders P.J.F., Helmerhorst T, Kenemans P., Walboomers J.M. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. In: Munoz N., Bosch F.X., Shah K.V., Meheus A. (eds.) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 271-281.

Miller B.J., WangD., KraheR., Wright F.A. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am. J. Hum. Genet., 2003, v. 73, p. 748-767.

Miller G. Prostate cancer among the Chinese: pathologic, epidemiologic and nutritional considerations. In: Advanced therapy of prostate disease (ed. Resnick M.I., Thompson I.M.), B.C. Decker, London, 2000, p. 18-27.

Miller W.R. Biological rationale for endocrine therapy in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab., 2004, v. 18, p. 1—32.

Mitelman F„ Mertens F., Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet., 1997, v. 15, p. 417—474.

Mitrani-Rosenbaum S., Tsvieli R., Lavie O., Boldes R., Anteby E., Shimonovitch

S., Lazarovitch T., Friedmann A. Simultaneous detection of three common sexually transmitted agents by polymerase chain reaction. Am. J. Obstet. Gynecol., 1994, v. 171, p. 784-790.

Moch H., Schraml P., Bubendorf L., Mirlacher M., Kononen J., Gasser T., Mihatsch M.J., Kallioniemi O.P., SauterG. High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am. J. Pathol, 1999, v. 154, p. 981—986.

Mokbel K. The role of telomerase in breast cancer. Eur. J. Suig. Oncol., 2000, v. 26, p. 509-514.

Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F„ Gambacorta M., SienaS., BardelliA. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol., 2005, v. 6, p. 279—286.

Murray TV., Salgia R., Fossella F. V. Targeted molecules in small cell lung cancer. Semin. Oncol., 2004, v. 31 (1 Suppl.l), p. 106-111.

Moon C, Oh Y., Roth J.A. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res., 2003, v. 9, p. 5055—5067.

MorrisS. W., Kirstein M.N., ValentineM.B., DittmerK.G., ShapiroD.N., SaltmanD.L., Look A.T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin’s lymphoma. Science, 1994, v. 263, p. 1281-1284.

Motzer R.J., Bacik J., Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6302S—6303S.

Muller A., Fishel R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Invest, 2002, v. 20, p. 102—109.

Muller M. Telomerase: its clinical relevance in the diagnosis of bladder cancer. Oncogene, 2002, v. 21, p. 650-655.

Muller O. Identification of colon cancer patients by molecular diagnosis. Dig. Dis., 2003, v. 21, p. 315-319.

Munoz N., Bosch F.X. HPV and cervical neoplasia: review of case-control and cohort studies. In: Munoz N., Bosch F.X., Shah K.V., Meheus A. (eds.) The

Список литературы

epidemiology of cervical and human papillomavirus. Lyon, France: I ARC, 1992, p. 251-261.

Munoz N., Kato /., Bosch F.X., Eluf-Neto J., De Sanjose S., Ascunce N., Gili M., Izarzugaza Viladiu P., Tormo M.J., Moreo P., Gonzalez L.C., TafurL., Walboomers J.M., Shah К. V. Risk factor for HPV DNA detection in middle-aged women. Sex. Transm. Dis., 1996, p. 504—510.

Narod S.A. Genetics of breast and ovarian cancer. Br. Med. Bull., 1994, v. 50, p. 656-676.

Nathan P.D., Eisen T.G. The biological treatment of renal-cell carcinoma and melanoma. Lancet Oncol., 2002, v. 3, p. 89—96.

Neuhausen S.L, Ostrander EA. Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2. Genet. Test., 1997, v. 1, p. 75—83.

Nishioka M., Kohno T., Tani M., Yanaihara N., Tomizawa Y., OtsukaA., Sasaki

5., Kobayashi K., Niki T., Maeshima A., Sekido Y., Minna J.D., Sone S., Yokota J. MY018B, a candidate tumor suppressor gene at chromosome 22ql2.1, deleted, mutated, and methylated in human lung cancer. Proc. Natl. Acad. Sci. USA, 2002, v. 99, p. 12269-12274.

Noble E.P. The DRD2 gene, smoking, and lung cancer. J. Natl. Cancer Inst., 1998, v. 90, p. 343-345.

Nomura A.M., Kolonel L.N. Prostate cancer: a current perspective. Epidemiol. Rev. 1991, v. 13, p. 200-227.

Ochiai T., Nishimura K., Noguchi H., KitajimaM., TsukadaA., WatanabeE., Nagaoka

1., Futagawa S. Prognostic impact of orotate phosphoribosyl transferase among 5-fluorouracil metabolic enzymes in resectable colorectal cancers treated by oral 5-fluorouracil-based adjuvant chemotherapy. Int. J. Cancer, 2006, v. 118, p. 3084—3088.

Omura K. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines. Int. J. Clin. Oncol., 2003, v. 8, p. 132—138.

Onyango P. Genomics and cancer. Curr. Opin. Oncol., 2002, v. 14, p. 79-85.

Oosterhuis J. W., Looijenga L.H. Testicular germ-cell tumours in a broader perspective. Nat. Rev. Cancer, 2005, v. 5, p. 210-222.

O’Regan R.M., Jordan V.C. The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators. Lancet Oncol., 2002, v. 3, p. 207-214.

Orsetti B., Courjal F., Сипу M., Rodriguez C., Theillet С. 17q21 -q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene, 1999, v. 18, p. 6262-6270.

Otto W.R. Lung epithelial stem cells. J. Pathol., 2002, v. 197, p. 527—535.

PaezJ.G., Janne P.A., LeeJ.C., Tracy S., Greulich H., GabrielS., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, v. 304, p. 1497-1500.

Pantuck A.J., ZengG., Belldegrun A.S., Figlin R.A. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin. Cancer Res., 2003, v. 9, p. 4641—4652.

Pao C.C., Kao S.M., Tang G.C., Lee K., Si J., Ruan S. Prevalence of human papillomavirus DNA sequences in an area with very high incidence of cervical carcinoma. Br. J. Cancer, 1994, v. 70, p. 694-696.

Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria /., Singh B., Heelan R., Rusch V, Fulton L., MardisE., KupferD., Wilson R., KrisM., VarmusH. EGFreceptor gene mutations are common in lung cancers from «never smokers» and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA, 2004, v. 101, p. 13306-13311.

Papadopoulos N., LindblomA. Molecular basis ofHNPCC: mutations of MM R genes. Hum. Mutat., 1997, v. 10, p. 89-99.

Park K., Kim J., Lim S., Han S. Topoisomerase II-alpha (topoll) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy. Eur. J. Cancer, 2003, v. 39, p. 631—634.

Parle-McDermott A., McWilliam P., Tighe O., Dunican D., Croke D.T. Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines. Br. J. Cancer, 2000, v. 83, p. 725—728.

Pastore G., Magnani C., Verdecchia A., Pession A., Viscomi S., Coebergh J.W. Survival of childhood lymphomas in Europe, 1978—1992: a report from the EUROCARE study. Eur. J. Cancer, 2001, v. 37, p. 703-710.

Papapolychroniadis C. Environmental and other risk factors for colorectal carcinogenesis. Tech. Coloproctol., 2004, v. 8, Suppl. 1, p. S7—S9.

Parada L.F., Tabin C.J., Shih C., Weinberg R.A. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature, 1982, v. 297, p. 474-478.

Parkin D.M., Whelan S.L., FerlayJ., Raymond L., Young J. Cancer incidence in five continents, v. VII. IARC Scientific Publications, № 143, International Agency for Research on Cancer, Lyon, 1997.

Pattari S.K, Dey P. Urine: beyond cytology for detection of malignancy. Diagn. Cytopathol., 2002, v. 27, p. 139-142.

Pasche B., Mulcahy M., Benson A.B., 3rd. Molecular markers in prognosis of colorectal cancer and prediction of response to treatment. Best. Pract. Res. Clin. Gastroenterol., 2002, v. 16, p. 331-345.

Pearse A.G. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APU D series and the embryologic, physiologic and pathologic implications of the concept. J. Histochem. Cytochem., 1969, v. 17, p. 303—313.

Peters M.A., Jarvik G.P., Janer M., Chakrabarti L., Kolb S., Goode E.L., Gibbs M., DuBoisC.C., Schuster E.F., HoodL., OstranderEA., Stanford J.L. Genetic linkage analysis of prostate cancer families to Xq27-28. Hum. Hered., 2001, v. 51, p. 107—113.

Perou C.M., Jeffrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T., PergamenschikovA., WilliamsC.F., ZhuS.X., LeeJ.C., Lashkari D., Shalon D., Brown P.O.,

Список литературы

Botstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. USA, 1999, v. 96, p. 9212-9217.

PerouC.M., Sortie T., Eisen M.B., vandeRijn M., JeffreyS.S., ReesC.A., Pollack J.R., Ross D. T., Johnsen H., Akslen L.A., Huge O., Pergamenschikov A., Williams C, Zhu S.X., Lonning P.E., Borresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature, 2000, v. 406, p. 747-752.

Phillips H.A. The role of the p53 tumour suppressor gene in human breast cancer. Clin. Oncol. (R. Coll. Radiol.), 1999, v. 11, p. 148-155.

Pollack J.R., PerouC.M., Alizadeh A.A., Eisen M.B., Pergamenschikov A., WilliamsC.F., Jeffrey S.S., Botstein D., Brown P.O. Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat. Genet., 1999, v. 23, p. 41—46.

Ponder B.A.J. Familial cancer: opportunities for clinical practice and research. Eur. J. Suig. Oncol., 1997, v. 13, p. 463-473.

Ponder B. Genetic testing for cancer risk. Science, 1997, v. 278, p. 1050—1054. Popov A.A. Family planning and induced abortion in the USSR: basic health and demographic characteristics. Stud. Fam. Plann., 1991, v. 22, p.368—377.

Potti A., George D.J. Tyrosine kinase inhibitors in renal cell carcinoma. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6371S-6376S.

Powell SM. Direct analysis for familial adenomatous polyposis mutations. Mol. Biotechnol., 2002, v. 20, p. 197—207.

Prendergast N.J., Walther P.J. Genetic alterations in prostate adenocarcinoma. Surg. Oncol. Clin. N. Am., 1995, v. 4, p. 241—255.

Proctor R.N. Tobacco and the global lung cancer epidemic. Nat. Rev. Cancer, 2001, v. l,p. 82-86.

Pusztai L., RouzierR., Wagner P., Symmans W.F. Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible? Drug Resist. Updat., 2004, v. 7, p. 325-331.

Quek M.L., Quinn D.I., Daneshmand S., Stein J.P. Molecular prognostication in bladder cancer — a current perspective. Eur. J. Cancer, 2003, v. 39, p. 1501—1510.

Quesnel S., Malkin D. Genetic predisposition to cancer and familial cancer syndromes. Pediatr. Clin. North. Am., 1997, v. 44, p. 791—808.

Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer, 2003, v. 97, Suppl. 8, p. 2083—2089.

Ramaswamy S., Sellers W.R. PTEN: a prostate cancer tumour-supressor gene. Prostate J., 2000, v. 2, p. 55—61.

Rebbeck T.R. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol. Biomarkers Prev., 1997, v. 6, p. 733—743.

ReffM. E., Heard C. A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications. Crit. Rev. Oncol. Hematol., 2001, v. 40, p. 25-35.

Reuter V.E. Origins and molecular biology of testicular germ cell tumors. Mod. Pathol., 2005, v. 18, Suppl. 2, p. S51—S60.

Richardson Н., Franco Е., Pintos J., Bergeron J., Arella M., TellierP. Determinants of low-risk and high-risk cervical human papillomavirus infections in Montreal University students. Sex. Transm. Dis., 2000, v. 27, p. 79-86.

Richter J., Wagner (J., Kononen J., Fijan A., BrudererJ., Schmid U., Ackermann D., Maurer R., Alund G., Knonagel H., Rist M., Wilber K., Anabitarte M., Hering F., Hardmeier T., SchonenbergerA., Flury R., JagerP., FehrJ.L., Schraml P., Moch H., Mihatsch M.J., Gasser T., Kallioniemi O.P., Sauter G. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am. J. Pathol., 2000, v. 157, p. 787—794.

RiesL.A.G., KosaryC.L., HankeyB.F., HarrasA., Miller B.A., EdwardsB.K. (eds). SEER cancer statistics review, 1973-1993: tables and graphs, National Cancer Institute. Bethesda, 1996.

Riggs B.L., Hartmann L.C. Selective estrogen-receptor modulators — mechanisms of action and application to clinical practice. N. Engl. J. Med., 2003, v. 348, p. 618—629.

Rindi G., Bordi C. Highlights of the biology of endocrine tumours of the gut and pancreas. Endocr Relat Cancer, 2003, v. 10, p. 427—436.

RisingerJ.L, MaxwellG.L.,ChandramouliG.V., JazaeriA., AprelikovaO., Patterson T., BerchuckA., Barrett J.C. Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res., 2003, v. 63,

p. 6-11.

Robert J., Vekris A., Pourquier P, Bonnet J. Predicting drug response based on gene expression. Crit. Rev. Oncol. Hematol., 2004, v. 51, p. 205—227.

Robert J., Morvan V.L., Smith D., Pourquier P, Bonnet J. Predicting drug response and toxicity based on gene polymorphisms. Crit. Rev. Oncol. Hematol., 2005, v. 54, p. 171-196.

Rolon P.A., Smith J.S., Munoz N., Klug S.J., Herrero R., Bosch X., Llamosas F., MeijerCJ., Walboomers J.M. Human papillomavirus infection and invasive cervical cancer in Paraguay. Int. J. Cancer, 2000, v. 85, p. 486—491.

Resell R., Taron M., Ariza A., Bamadas A., Mate J.L., Reguart N., Margel M., Felip E., Mendez P-, Garcia-Campelo R. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol., 2004, v. 31 (1 Suppl.l), p. 20—27.

Resell R., Cobo M., Isla D., Sanchez J.M., Taron M., Altavilla G., Santarpia M., Moran T, Catot S., Etxaniz O. Applications of genomics in NSCLC. Lung Cancer, 2005, v. 50, Suppl. 2, S33-S40.

Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., Gascoyne R.D., Muller-Hermelink H.K., SmelandE.B., Giltnane J.M., HurtE.M., Zhao H., AverettL., YangL., Wilson W.H.,Jaffe E.S., Simon R., Klausner R.D., Powell J., Duffey P.L., Longo D.L., Greiner T.C., Weisenburger D.D., Sanger W.G., Dave B.J., Lynch J.C., VoseJ., Armitage J.O., Montserrat E., Lopez-Guillermo A., Grogan T.M., Miller

T.P., LeBlanc M., Ott G., Kvaloy S., Delabie J., Holte H., Krajci P., Stokke T., Staudt L.M.; Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-В-cell lymphoma. N. Engl. J. Med., 2002, v. 346, p. 1937-1947.

Список литературы

Ross J.S., Sheehan С.Е., Hayner-Buchan A.M., Ambros R.A., Kallakury B.V., Kaufman R.P. Jr., Fisher H.A., Rifkin M.D., Muraca P.J. Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma. Cancer, 1997, v. 79, p. 2162-2170.

RossJ.S., Fletcher J.A., LinetteG.P., StecJ., Clark E., Ayers M., Symmans W.F., Pusztai L., Bloom K.J. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist, 2003, v. 8, p. 307-325.

RouzierR., Rajan R., Wagner P., Hess K.R., Gold D.L., StecJ., Ayers M., RossJ.S., ZhangP., Buchholz T.A., KuererH., Green M.,Arun B., HortobagyiG.N., Symmans W.F., Pusztai L. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc. Natl. Acad. Sci. USA, 2005, v. 102, p. 8315—8320.

Rubin H. Cell aging in vivo and in vitro. Mech. Aging Dev., 1998, v. 97, p. 1-35.

RudolfM.P., Man S., MeliefC.J., SetteA., Kast W.M. Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7. Clin. Cancer Res., 2001, v. 7 (3 Suppl.), p. 788s-795s.

Ruijter E., van de Kaa C., Miller G., Ruiter D., Debruyne F, Schalken J. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev., 1999, v. 20, p. 22—45.

Santen R.J. Inhibition ofaromatase: insights from recent studies. Steroids, 2003, v. 68, p. 559-567.

Saric T., Brkanac Z., Troyer D.A., Padalecki S.S., Sarosdy M., Williams K., Abadesco L., Leach R.J., O’Connell P. Genetic pattern of prostate cancer progression. Int. J. Cancer, 1999, v. 81, p. 219-224.

Sasieni P. D. Human papillomavirus screening and cervical cancer prevention. J. Am. Med. Womens Assoc., 2000, v. 55, p. 216—219.

Sawyers C. Targeted cancer therapy. Nature, 2004, v. 432, p. 294—297.

Scandinavian Breast Group Trial 9401; Tanner M., IsolaJ., Wiklund T, Erikstein B., Kellokumpu-Lehtinen P, Malmstrom P, WilkingN., Nilsson J., Bergh J. Topoisomerase Ilalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol., 2006, v. 24, p. 2428-2436.

ScheffnerM., Romanczuk H., MungerK., HuibregtseJ.M., MietzJ.A., HowleyP.M. Function of human papillomavirus proteins. Curr. Top. Microbiol. Immunol., 1994, v. 186, p. 83-96.

Schiffman M.H. Epidemiology of cervical human papillomavirus infections. Curr.Top. Microbiol. Immunol., 1994, v. 186, p. 55—81.

Shigematsu H., Lin L., Takahashi T., Nomura M., SuzukiM., Wistuba 1.1., FongK.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., FengZ., Roth J.A., Herz J., Minna J.D., GazdarA.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, v. 97, p. 339— 346.

Schmoll H.J. Extragonadal germ cell tumors. Ann Oncol., 2002, v. 13, Suppl. 4, p. 265-272.

Schneider A., Koutsky L. Natural history and epidemiology features of genital HPV infection. In: Munoz N., Bosch F.X., Shah K.V., Meheus A. (eds.) The epidemiology of cervical and human papillomavirus. Lyon, France: IARC, 1992, p. 25—52.

Sellers E.M., Tyndale R.F., Fernandes L.C. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discov. Today, 2003, v. 8, p. 487—493.

Sen F., Vega F., Medeiros L.J. Molecular genetic methods in the diagnosis of hematologic neoplasms. Semin. Diagn. Pathol., 2002, v. 19, p. 72-93

Seve P., IsaacS., Tredan O., Souquet P.J., Pacheco Y., PerolM., Lafanechere L., PenetA., Peiller E.L., Dumontet C. Expression of class III beta-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin. Cancer Res., 2005, v. 11, p. 5481—5486.

Sgroi D.C., Teng S., Robinson G., LeVangie R., Hudson J.R. Jr, Elkahloun A.G. In vivo gene expression profile analysis of human breast cancer progression. Cancer Res., 1999, v. 59, p. 5656-5661.

Shigematsu H., Lin L., Takahashi T, Nomura M., SuzukiM„ Wistuba 1.1., FongK.M., Lee H., Toyooka S., Shimizu N., Fujisawa T, FengZ., Roth J.A., HerzJ., Minna J.D., Gazdar A.F. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst., 2005, v. 97, p. 339—346.

Shipp M.A., RossK.N., Tamayo P, WengA.P., KutokJ.L., AguiarR.C., GaasenbeekM., Angelo M., Reich M., Pinkus G.S., Ray T.S., Koval M.A., Last K. W., Norton A., Lister ТА., Mesirov J., Neuberg D.S., Lander E.S., Aster J.C., Golub T.R. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med., 2002, v. 8, p. 68-74.

Shivapurkar N., Sood S., Wistuba II., Milchgrub S., Mackay B., Minna J.D., Gaidar A. F. Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas. Cancer Res., 1999, v. 59, p. 3576-3580.

Sidransky D. Emerging molecular markers of cancer. Nat. Rev. Cancer, 2002, v. 2, p. 210-219.

SinclairC.S., Berry R., Schaid D., Thibodeau S.N., Couch F.J. BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res., 2000, v. 60, p. 1371— 1375.

Smith I.E., Dowsett M. Aromatase inhibitors in breast cancer. N. Engl. J. Med., 2003, v. 348, p. 2431-2442.

Southern S.A., Herrington C.S. Molecular events in uterine cervical cancer. Sex. Transm. Infect., 1998, v. 74, p. 101—109.

Spierings D.C., de Vries E.G., Vellenga E., de Jong S. The attractive Achilles heel of germ cell tumours: an inherent sensitivity to apoptosis-inducing stimuli. J. Pathol., 2003, v. 200, p. 137-148.

Sridhar S.S., Shepherd F.A. Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer, 2003, v. 42, Suppl. 1, p. S81-S91.

St Croix B., Rago C., Velculescu V., LeVangie R., Hudson J.R. Jr, Elkahloun A.G. Genes expressed in human tumor endothelium. Science, 2000, v. 289, p. 1197—1202.

Список литературы

Stephens Р, Hunter С., Bignell G., Edkins S., Davies H., Teague J., Stevens C., O’Meara S., Smith R., Parker A., Barthorpe A., Blow M., Brackenbury L., Butler A., Clarke O., ColeJ., Dicks E., Dike A., Drozd A., Edwards K., Forbes S., Foster R., Gray K., GreenmanC., HallidayK., Hills K, Kosmidou V., LuggR., MenziesA., Perry J., Petty R., Raine K., Ratford L., Shepherd R., Small A., Stephens Y., Tofts C., VarianJ., WestS., Widaa S., Yates A., BrasseurF., Cooper C.S., Flanagan A. M., Knowles M., LeungS. Y., Louis D.N., Looijenga L.H., Malkowicz B., Pierotti M.A., Teh B., Chenevix- Trench G., WeberB.L., YuenS.T., HarrisG., GoldstrawP, Nicholson A.G., FutrealP.A., WoosterR., Stratton M.R. Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature, 2004, v. 431, p. 525-526.

Stern P.L., Brown M., Stacey S.N., KitchenerH.C., Hampson /., Abdel-Hady E.S., Moore J.V. Natural HPV immunityand vaccination strategies. J. Clin. Virol., 2000, v. 19, p. 57—66

Stohlmacher J. Pharmacogenetics in gastrointestinal tumors. Onkologie, 2005, v. 28, p. 435-440.

Swerdlow A.J., Barber J.A., Hudson G.V., Cunningham D., Gupta R.K., Hancock B.W., HorwichA., ListerT.A., LinchD.C. Riskofsecond malignancy after Hodgkin’s disease in a collaborative British cohort: the relation to age at treatment. J. Clin. Oncol., v. 18, p. 498-509.

Swerdlow A., dos Santos S., Doll R. Cancer Incidence and Mortality in England and Wales: trends and risk factors. Oxford University Press, 2001.

Swerdlow A..J. Epidemiology of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 2003, v. 30, p. S3—SI2.

Syrjanen K, Syrjanen S. Epidemiology of human papillomavirus infection and genital neoplasia. Scand. J. Infect. Dis. Suppl., 1990,. v. 69, p. 7—17.

Syrjanen K. Human papillomavirus in genital carcinogenesis. Sex. Transm. Dis., 1994, v. 21, p. S86-S89.

Taioli E., Trachman J., Chen X., Toniolo P., Garte S.J. A CYP1A1 restriction fragment length polymorphism is associated with breast cancer in African-American women. Cancer Res., 1995, v. 55, p. 3757—3758.

Tan M.H., Rogers C.G., CooperJ.T., DitlevJ.A., Maatman T.J., YangX., Furge K.A., The B.T Gene expression profiling of renal cell carcinoma. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6315S—632IS.

Tang Y.M., Green B.L., Chen G.F., Thompson P.A., LangN.P., ShindeA., Lin D.X., Tan W., Lyn-Cook B.D., Hammons G.J., Kadlubar F.F. HumanCYPIBl Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics, 2000, v. 10, p. 761—766.

Tavtigian S. V., SimardJ., TengD.H., Abtin V., Baumgard M., Beck A., Camp N.J., CarilloA.R., Chen Y., Dayananth P., DesrochersM., Dumont M., FamhamJ.M., Frank D., Frye C., Ghaffari S., Gupte J.S., Hu R., Iliev D., Janecki T, Kort E.N., Laity K.E., Leavitt A., Leblanc G., McArthur-Morrison J., Pederson A., Penn B., Peterson K.T., Reid J.E., Richards S., Schroeder M., Smith R., Snyder S.C., Swedlund B., Swensen J.,

Thomas Л., Tranchant М., Woodland А.М., Labrie F., Skolnick М.И., Neuhausen S., Rommens J., Cannon-Albright L.A. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet., 2001, v. 27, p. 172-180.

Taupenot L., Harper K.L., O’Connor D.T. The chromogranin-secretogranin family. N. Engl. J. Med., 2003, v. 348, p. 1134—1149.

Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histol. Histopathol., 2003, v. 18, 259-274.

Toffoli G., Veronesi A., Boiocchi M., Crivellari D. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF). Ann. Oncol., 2000, v. 11, p. 373-374.

ToffoliG., Russo A., Innocenti F., CoronaG., ThmoloS., Sartor F., MiniE., Boiocchi M. Effect of methylenetetrahydrofolate reductase 677C—>T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int. J. Cancer, 2003, v. 103, p. 294—299.

Tonon S.A., Picconi M.A., Zinovich J.B., Liotta D.J., Bos P.D., Galuppo J.A., Alonio L. V., FerrerasJ.A., Teyssie A. R. Human papillomavirus cervical infection and associated risk factors in a region of Argentina with a high incidence of cervical carcinoma. Infect. Dis. Obstet. Gynecol., 1999, v. 7, p. 237-243.

Trapeznikov N.N., Aksel E.M. Cancer incidence and mortality in Russia and CIS in 1998. N.N. Blokhin Russian Cancer Research Center, Moscow, 2000.

Tsao M.S., Sakurada A., CutzJ.C., Zhu C.Q., Kamel-Reid S., Squire J., LorimerL, Zhang T., Liu N., Daneshmand M., Marrano P., da Cunha Santos G., Lagarde A., Richardson F., Seymour L., Whitehead M., DingK, Pater J., Shepherd F.A. Erlotinib in lung cancer — molecular and clinical predictors of outcome. N. Engl. J. Med., 2005, v. 353, p. 133-144.

Tsuchida Y., Hemmi H., Inoue A., Obana K., YangH.W., Hayashi Y., Kanda N., Shimatake H. Genetic clinical markers of human neuroblastoma with special reference to N-myc oncogene: amplified or not amplified?—An overview. Tumour Biol., 1996, v. 17, p. 65-74.

Tyring S.K. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J. Am. Acad. Dermatol., 2000, v. 43, p. S18-S26.

Ulrich C.M., Yasui Y., Storb R., Schubert M.M., Wagner J.L., Bigler J., Ariail K.S., Keener C.L., Li S., Liu H., Farin F.M., Potter J.D. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 2001, v. 98, p. 231-234.

Urano N., Fujiwara Y., Doki Y., Kim S.J., Miyoshi Y., Noguchi S., Miyata H., Takiguchi S., Yasuda T, Yano M., Monden M. Clinical significance of class III beta-tubulin expression and its predictive value for resistance to docetaxel-based chemotherapy in gastric cancer. Int. J. Oncol., 2006, v. 28, p. 375—381.

Vahteristo P., BartkovaJ., Eerola H., Syrjakoski K, Ojala S., Kilpivaara O., Tamminen A., Kononen J., Aittomaki K, Heikkila P., Holli K, BlomqvistC., BartekJ., Kallioniemi

Список литературы

О.Р., Nevanlinna Н. А СНЕК.2 genetic variant contributing to a substantial fraction of familial breast cancer. Am. J. Hum. Genet., 2002, v. 71, p. 432—438.

Van Herpen C.M., De Mulder P.H. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma. Crit. Rev. Oncol. Hematol., 2002, v. 41, p. 327-334.

Van KuilenburgA.B., Meinsma R., Zoetekouw L., Van GennipA.H. Increased risk of grade IV neutropenia after administration of 5-fluorouraciI due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+lg>a mutation. Int. J. Cancer, 2002, v. 101, p. 253-258.

Van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer, 2004, v. 40, p. 939-950.

Velculescu V.E., Madden S.L., Zhang L., LashA.E., YuJ., RagoC., Lai A., WangC.J., Beaudry G.A., Ciriello K.M., CookB.P., DufaultM.R., FergusonA.T., Gao Y., He T.C., Hermeking H., Hiraldo S.K., Hwang P.M., Lopez M.A., Luderer H.F., Mathews B., Petroziello J.M., Polyak K., Zawel L., Kinzler K.W., et al. Analysis of human transcriptomes. Nat. Genet., 1999, v. 23, p. 387—388.

Velculescu V.E., Zhang L., Vogelstein B., Kinzler КЖ. Serial analysis of gene expression. Science, 1995, v. 270, p. 484—487.

VijgJ., Wei J. Y. Understanding the biology of aging: the key to prevention and therapy. J. Am. Geriatr. Soc, 1995, v. 43, p. 426—434.

Villa L.L. Human papillomaviruses and cervical cancer. Adv. Cancer Res., 1997, v. 71, p. 321-341.

Vine is P, Caporaso N. The analysis of restriction fragment length polymorphism in human cancer: a review from an epidemiological perspective. Int J. Cancer, 1991; v. 47, p. 26—30.

von Eyben F.E. Chromosomes, genes, and development of testicular germ cell tumors. Cancer Genet. Cytogenet., 2004, v. 151, p. 93—138.

VoseJ.M., Chiu B.C., Cheson B.D., DanceyJ., Wright J. Updateon epidemiology and therapeutics for non-Hodgkin’s lymphoma. Hematology (Am Soc Hematol Educ Program). 2002, p. 241—262.

WalboomersJ.M.M., Melkert P. W.J., Van den Brule A.J.C. The polymerase chain reaction for human papillomavirus screening in diagnostic cytopathology of the cervix. In: Herrington C.S., McGee J.O.D. (eds.) Diagnostic Molecular Pathology. A Practical Approach. Oxford: IRL Press, 1992, p. 153-172.

Wang T., Hopkins D., Schmidt C., Silva S., Houghton R., Takita H., Repasky E., Reed S.G. Identification of genes differentially over-expressed in lung squamous cell carcinoma using combination of cDNA subtraction and microarray analysis. Oncogene, 2000, v. 19, p. 1519-1528.

Warmuth M.A., Sutton L.M., Winer E.P. A review of hereditary breast cancer: from screening to risk factor modification. Am. J. Med., 1997, v. 102, p. 407—415.

Watanabe M., Nakayama T., Shiraishi T., Stemmermann G.N., Yatani R. Comparative studies of prostate cancer in Japan versus the United States. A review. Urol. Oncol., 2000, v. 5, p. 274-283.

Watters J.W., McLeod H.L. Cancer pharmacogenomics: current and future applications. Biochim. Biophys. Acta, 2003, v. 1603, p. 99—111.

Welcsh P.L., Owens K.N., King M.C. Insights into the functions of BRCA1 and BRCA2. Trends Genet., 2000, v. 16, p. 69-74.

Weston A., Godbold J.H. Polymorphisms of H-ras-1 and p53 in breast cancer and lung cancer: a meta-analysis. Environ. Health Perspect, 1997, v. 105, Suppl. 4, p. 919-926.

Wick M.J. Diagnosis of human papillomavirus gynecologic infections. Clin. Lab. Med., 2000, v. 20, p. 271-287.

Widschwendter M., Jones, P.A. DNA methylation and breast carcinogenesis. Oncogene, 2002, v. 21, p. 5462-5482.

Wotherspoon A.C. Helicobacter pylori infection and gastric lymphoma. Br. Med. Bull., 1998, v. 54, p. 79-85.

Wynder E., Hoffman D. Smoking and lung cancer: challenges and opportunities. Cancer Res., 1997, v. 54, p. 1580—1586.

Xu L.L., Srikantan V., Sesterhenn I.A., Augustus M., Dean R., Moul J.W., Carter K.C., Srivastava S. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J. Urol., 2000, v. 163, p. 972-979.

Yandell D.W., Poremba C. Genetics of retinoblastoma: implications for other human cancers. Med. Pediatr. Oncol. (Suppl.), 1996, v. 1, p. 25—28

Yang J.C. Bevacizumab for patients with metastatic renal cancer: an update. Clin. Cancer Res., 2004, v. 10 (18 Pt 2), p. 6367S-6370S.

Ye S.Q., Zhang L.Q., Zheng F., Virgil D., Kwiterovich P.O. miniSAGE: gene expression profiling using serial analysis of gene expression from 1 microg total RNA. Anal. Biochem., 2000, v. 287, p. 144-152.

Yu M.C., Skipper P.L., Tannenbaum S.R., Chan K.K., Ross R.K. Arylamine exposures and bladder cancer risk. Mutat. Res., 2002, v. 506-507, p. 21-28.

Zhang W., Laborde P.M., Coombes K.R., Berry D.A., Hamilton S.R. Cancer genomics: promises and complexities. Clin. Cancer. Res., 2001, v. 7, p. 2159—2167.

Zhou B.B., Elledge S.J. The DNA damage response: putting checkpoints in perspective. Nature, 2000, v. 408, p. 433—439.

Zhou W., SokollL.J., BruzekD.J., ZhangL., Velculescu V.E., Goldin S.B., Hruban R.H., Kern S.E., Hamilton S.R., Chan D.W., Vogelstein B., Kinzler K.W. Identifying markers for pancreatic cancer by gene expression analysis. Cancer Epidemiol. Biomarkers Prev., 1998, v. 7, p. 109—112.

ZhouX.P., HoangJ.M., Li Y.J., Cameiro F., Sobrinho-Simoes M., Lothe R.A., Gleeson C.M., Russell S.E., Muzeau F, FlejouJ.F., Hoang-Xuan K, Lidereau R., Thomas G., Hamelin R. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer, 1998, v. 21, p. 101—107.

Zochbauer-MullerS., Minna J.D., GazdarA.F. Aberrant DNA methylation in lung cancer: biological and clinical implications. Oncologist, 2002, v. 7, p. 451—457.

Список литературы

zur Hausen Н. Papillomavirus infection — a major cause of human cancer. Biochim. Biophys. Acta, 1996, v. 1288, p. 55—78.

zur Hausen H. Viruses in human cancers. Eur. J. Cancer, 1999, v. 35, p. 1878— 1885.

Е. Н. Имянитов, К. П. Хансон

В авторской редакции Оригинал-макет Д. М. Зарецкая

Подписано в печать 28.02.2007. Формат бумаги 60х84716. Бумага офсетная. Гарнитура NewtonC. Печать офсетная. Уел. печ. л. 123,5. Тираж 1000 экз. Заказ № 3956

Санкт-Петербург, Издательский дом СПбМАПО 191015, Санкт-Петербург, Кирочнаяул., д. 41.

Отпечатано с готовых диапозитивов в ГУП «Типография «Наука»

199034, Санкт-Петербург, 9линия, 12

Молекулярная онкология, клинические аспекты, Е.Н. Имянитов, К.П. Хансон